Trial Profile
An Open-label, Observational 12-week Study to Assess Health-related Quality of Life and Patient-reported Outcomes in Patients With Rheumatoid Arthritis Treated With Certolizumab Pegol
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Certolizumab pegol (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SONAR-12
- Sponsors UCB Pharma SA
- 14 Mar 2014 According to the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 12 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 May 2013 Planned end date changed from 1 Nov 2013 to 1 Feb 2014 as reported by ClinicalTrials.gov.